FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Development and validation of nomograms to evaluate the survival outcome of HCC patients undergoing selective postoperative adjuvant TACE. PMID 38512609 · Radiol Med · 2024-Apr The study is a retrospective analysis of clinical data to develop and validate prognostic nomograms for HCC patients. Although it mentions 'randomly allocated' for cohort splitting, it is not a randomized controlled trial comparing intervention vs. control. The publication type 'Randomized Controlled Trial' appears to be a metadata error, as the methods describe a retrospective cohort study. Therefore, it fails the required criteria for being a randomized trial and lacks evidence of Phase III/IIIb or Phase II/III status. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| MIRO study: Do the results of a randomized controlled trial apply in a real population? PMID 38490752 · Surgery · 2024-Apr The record is a secondary analysis of a prior RCT, not an original trial report. It is a non-randomized cohort study focusing on surgical approaches for a postoperative complication endpoint, lacking a drug intervention and time-to-event efficacy outcomes (OS, PFS, etc.). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Survival and cancer recurrence after short-course perioperative probiotics in a randomized trial. PMID 38479940 · Clin Nutr ESPEN · 2024-Apr The study is a randomized trial of a probiotic (VSL#3) versus placebo in patients undergoing surgery for visceral malignancy. While it is oncology, human, randomized, reports time-to-event endpoints (OS, PFS), and is an original result, the intervention is a probiotic, not a drug. The publication type is 'Randomized Controlled Trial' but no specific phase (III/IIIb or II/III) is mentioned in the abstract, publication types, or MeSH terms. The deterministic review correctly flags that phase evidence is unclear. The probiotic is a non-drug intervention, which excludes the record. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. PMID 38467131 · Lancet Oncol · 2024-Apr The study is an oncology, human, phase 3b trial with a drug intervention and reports original results. However, it is a single-arm (non-randomized) trial, and its primary activity endpoint is complete remission rate, a categorical response endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier survival analysis, or hazard ratio). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-Term Effect of Randomization to Calcium and Vitamin D Supplementation on Health in Older Women : Postintervention Follow-up of a Randomized Clinical Trial. PMID 38467003 · Ann Intern Med · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Bias of the additive hazard model in the presence of causal effect heterogeneity. PMID 38466520 · Lifetime Data Anal · 2024-Apr The record describes a methodological study analyzing bias in hazard models, using a clinical trial as an illustrative example. It is not an original, formal-result report of a randomized controlled trial's efficacy findings. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study. PMID 38463541 · JHEP Rep · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. PMID 38449794 · Oncol Lett · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials. PMID 38442809 · Crit Rev Oncol Hematol · 2024-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial. PMID 38440777 · Contemp Clin Trials Commun · 2024-Apr The record is a study protocol for a pilot randomized controlled trial. It explicitly describes a Phase II (pilot) study without reported results. The primary outcomes are feasibility and acceptability, not time-to-event efficacy endpoints. While the study involves pancreatic cancer patients on chemotherapy (implying drug intervention), there is no primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) reported or planned as a primary outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. PMID 38438735 · Nat Med · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Control4Life: A randomized controlled trial protocol examining the feasibility and efficacy of a combined pelvic health rehabilitation and exercise fitness program for individuals undergoing prostatectomy. PMID 38431130 · Contemp Clin Trials · 2024-Apr 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial. PMID 38428265 · Lung Cancer · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| 68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. PMID 38423030 · Lancet Oncol · 2024-Apr Eligibility fails due to missing key criteria: trial is single-arm (not randomized), intervention is an imaging diagnostic (no drug therapy), and primary endpoint is diagnostic performance (proportion detecting lesions), not a time-to-event efficacy endpoint like OS, PFS, etc. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. PMID 38422585 · Eur J Cancer · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia. PMID 38409530 · Leukemia · 2024-Apr 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study. PMID 38377732 · Breast · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan. PMID 38376651 · Hepatol Int · 2024-Apr The study is a Phase IV randomized trial, not Phase III/IIIb or Phase II/III. Furthermore, the primary efficacy endpoint (cumulative incidence of virological relapse) is not a standard time-to-event endpoint like OS, PFS, etc., but a binary outcome measured at fixed time points. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The ELECLA trial: A multicentre randomised control trial on outcomes of neoadjuvant treatment on locally advanced colon cancer. PMID 38362850 · Colorectal Dis · 2024-Apr This is a clinical trial protocol without reported results. While it describes a randomized trial with a time-to-event efficacy endpoint (PFS) and drug intervention, it does not present formal results (Kaplan-Meier curves, HR, etc.). The phase is not explicitly stated as Phase III or definitive Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. PMID 38351182 · Nat Cancer · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. PMID 38343151 · Am J Hematol · 2024-Apr The record describes the final long-term follow-up of the VIALE-A randomized Phase III trial in acute myeloid leukemia (human malignancy). It is a randomized controlled trial with a drug-containing intervention (venetoclax-azacitidine) and a primary time-to-event efficacy endpoint (OS). The abstract explicitly states it is a randomized study, presents final OS data (including HR and Kaplan-Meier estimates), and is not a subgroup, biomarker-only, or safety-only analysis. Phase III is implied by the definitive trial design and large randomized population, meeting criteria for a definitive trial report. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Early Complications and Outcome After Treatment of Ruptured Aneurysms in Patients with Subarachnoid Hemorrhage-A Post Hoc Analysis of the EARLYDRAIN Trial. PMID 38340802 · World Neurosurg · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of FRAilty screening and Geriatric assessment and INtervention in older patients with epithelial Ovarian Cancer: A multicenter randomized clinical trial protocol (FRAGINOC). PMID 38326125 · J Geriatr Oncol · 2024-Apr 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial. PMID 38316193 · Radiother Oncol · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Shared decision making with breast cancer patients - does it work? Results of the cluster-randomized, multicenter DBCG RT SDM trial. PMID 38316191 · Radiother Oncol · 2024-Apr Study is a randomized trial in breast cancer patients assessing a patient decision aid (non-drug intervention) with patient-reported engagement as the primary endpoint, not a time-to-event efficacy outcome (e.g., OS, PFS, DFS, HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted radical resection of colorectal cancer using the KangDuo surgical robot versus the da Vinci Xi robotic system: short-term outcomes of a multicentre randomised controlled noninferiority trial. PMID 38307959 · Surg Endosc · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intraoperative Music to Promote Patient Outcome (IMPROMPTU): A Double-Blind Randomized Controlled Trial. PMID 38306934 · J Surg Res · 2024-Apr The study is a randomized, double-blind trial in oncology patients, but it does not involve a drug-containing intervention (the intervention is intraoperative music). Furthermore, the primary endpoint is postoperative pain (a patient-reported outcome), and secondary endpoints include complications, length of stay, and mortality, but no time-to-event efficacy endpoints (e.g., OS, PFS, DFS, HR, Kaplan-Meier analysis) are reported. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression. PMID 38299570 · J Urol · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial. PMID 38278333 · Radiother Oncol · 2024-Apr 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| A prognostic score system in adult T-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation. PMID 38267585 · Bone Marrow Transplant · 2024-Apr The study is a retrospective analysis of prognostic factors in adult T-ALL patients after HSCT, not a randomized trial of a drug-containing intervention. It is not a Phase III/IIIb or Phase II/III randomized trial, and there is no drug intervention (HSCT is a procedure). The randomization is for internal model validation, not a treatment comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer. PMID 38245661 · Br J Cancer · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A comparative evaluation of fibreoptic bronchoscopy versus C-MAC® D-BLADE-guided videolaryngoscopy for nasotracheal intubation under general anesthesia in oropharyngeal carcinoma surgery patients. PMID 38243098 · Can J Anaesth · 2024-Apr The study is an oncology RCT comparing procedural techniques for intubation in cancer patients, not a drug intervention trial. It lacks the required time-to-event efficacy endpoint (OS, PFS, etc.) and associated survival analysis (Kaplan-Meier, HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial. PMID 38231313 · Breast Cancer Res Treat · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Hypofractionated Whole Breast Irradiation (WBI) vs. Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5Years Update of the HYPAB Trial. PMID 38220538 · Clin Breast Cancer · 2024-Apr The study is a randomized, oncology trial with human subjects and reports primary results. However, it is excluded because the intervention is radiotherapy alone (no drug-containing intervention) and the primary efficacy endpoints are toxicity, cosmesis, and local relapse, with no time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Examining Moderation of Dignity Therapy Effects by Symptom Burden or Religious/Spiritual Struggles. PMID 38215893 · J Pain Symptom Manage · 2024-Apr The study is a randomized controlled trial in cancer patients, but the intervention is Dignity Therapy (a psychotherapeutic intervention), not a drug. The primary endpoints are quality-of-life and dignity-related outcomes, not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial. PMID 38175448 · Breast Cancer Res Treat · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Increasing bowel cancer screening using SMS in general practice: the SMARTscreen cluster randomised trial. PMID 38164588 · Br J Gen Pract · 2024-Apr The trial is an oncology randomized controlled trial with a primary result, but it is ineligible because it is not a drug intervention and does not report a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial. PMID 38153961 · J Urol · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401. PMID 38148124 · Int J Urol · 2024-Apr The record describes a randomized, drug-intervention trial with primary time-to-event efficacy endpoints (PSA-PFS, OS, rPFS) in oncology (prostate cancer). However, the trial phase (Phase II/III vs. Phase III) is not explicitly stated in the provided title, abstract, or publication metadata. Without explicit Phase III/IIIb or Phase II/III designation, the criterion for 'phase3_or_definitive' cannot be established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality of life measures and cost analysis of biologic versus synthetic mesh for ventral hernia repair: The Preventing Recurrence in Clean and Contaminated Hernias randomized clinical trial. PMID 38135553 · Surgery · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. PMID 38123789 · Breast Cancer Res Treat · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. PMID 38112922 · Breast Cancer Res Treat · 2024-Apr The record describes a single-arm, non-randomized Phase IIIb trial. While it is an oncology study with drug intervention, human subjects, and time-to-event endpoints, it fails the core eligibility criterion of being a randomized trial. Therefore, it is not eligible for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis. PMID 38013634 · J Cosmet Dermatol · 2024-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prognostic factors and novel nomograms for overall survival and cancer specific survival of malignant ovarian cancer patients with bone metastasis: A SEER-based study. PMID 38013509 · Int J Gynaecol Obstet · 2024-Apr The record is a retrospective prognostic study developing nomograms from a registry database (SEER). While it involves oncology, human patients, and time-to-event endpoints, it is not a randomized trial, does not test a specific drug intervention, and is not an original result report of a Phase III or II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Do medications increase the efficacy of digital interventions for smoking cessation? Secondary results from the iCanQuit randomized trial. PMID 38009551 · Addiction · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Machine learning based on SPECT/CT to differentiate bone metastasis and benign bone lesions in lung malignancy patients. PMID 37966123 · Med Phys · 2024-Apr The study is an oncology randomized trial in humans with original results. However, it is not a drug intervention study (no drug-containing arm), does not have a time-to-event efficacy endpoint (OS, PFS, etc., or Kaplan-Meier/HR analysis for such endpoints), and the trial phase is not explicitly stated (cannot infer from publication type alone). Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Linked-color imaging versus high definition white-light endoscopy for evaluation of post-polypectomy scars of nonpedunculated lesions: LCI-Scar study. PMID 37931908 · Endoscopy · 2024-Apr This is a randomized controlled trial in human oncology (colorectal neoplasms) reporting original primary results, but it is not eligible because it lacks a drug-containing intervention (it compares imaging modalities: LCI vs WLE), is not a Phase III trial (phase not specified, appears to be an endoscopic technique study), and does not have a primary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The outcome is diagnostic accuracy (sensitivity, NPV). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical characteristics and prognosis of patients with primary squamous cell carcinoma of the retromolar trigone: A SEER-based analysis. PMID 37923133 · J Stomatol Oral Maxillofac Surg · 2024-Apr The record describes a retrospective, population-based cohort study (using SEER data) that develops and validates prognostic nomograms. It is not a randomized clinical trial evaluating a drug intervention; the 'randomized' tag in the metadata refers to the statistical splitting of data into training/validation cohorts, not to patient randomization in a clinical trial. Therefore, it fails the core eligibility criteria of being a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. PMID 37815847 · Future Oncol · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role? PMID 37758610 · Dig Liver Dis · 2024-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |